Toward a Cancer Drug of Fungal Origin (Articolo in rivista)

Type
Label
  • Toward a Cancer Drug of Fungal Origin (Articolo in rivista) (literal)
Anno
  • 2015-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1002/med.21348 (literal)
Alternative label
  • Alexander Kornienko, Antonio Evidente, Maurizio Vurro, Veronique Mathieu, Alessio Cimmino, Marco Evidente, Willem A. L. van Otterlo, Ramesh Dasari, Florence Lefranc, Robert Kiss (2015)
    Toward a Cancer Drug of Fungal Origin
    in Medicinal research reviews (Online)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Alexander Kornienko, Antonio Evidente, Maurizio Vurro, Veronique Mathieu, Alessio Cimmino, Marco Evidente, Willem A. L. van Otterlo, Ramesh Dasari, Florence Lefranc, Robert Kiss (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1 - Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666 2 - Dipartimento di Scienze Chimiche, Universita di Napoli Federico II, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126, Napoli, Italy 3 - Institute of Sciences of Food Production, National Research Council, Via Amendola 122/0, 70126, Bari, Italy 4- Laboratorie de Cancerologie et de Toxicologie Experimentale, Faculte de Pharmacie, Universite Libre de Bruxelles (ULB), Brussels, Belgium 5 - Department of Chemistry and Polymer Science, University of Stellenbosch, Private Bag X1, Matieland, 7602, South Africa 6 - Service de Neurochirurgie, Hopital Erasme, Universite Libre de Bruxelles (ULB), Brussels, Belgium (literal)
Titolo
  • Toward a Cancer Drug of Fungal Origin (literal)
Abstract
  • Although fungi produce highly structurally diverse metabolites, many of which have served as excellent sources of pharmaceuticals, no fungi-derived agent has been approved as a cancer drug so far. This is despite a tremendous amount of research being aimed at the identification of fungal metabolites with promising anticancer activities. This review discusses the results of clinical testing of fungal metabolites and their synthetic derivatives, with the goal to evaluate how far we are from an approved cancer drug of fungal origin. Also, because in vivo studies in animal models are predictive of the efficacy and toxicity of a given compound in a clinical situation, literature describing animal cancer testing of compounds of fungal origin is reviewed as well. Agents showing the potential to advance to clinical trials are also identified. Finally, the technological challenges involved in the exploitation of fungal biodiversity and procurement of sufficient quantities of clinical candidates are discussed, and potential solutions that could be pursued by researchers are highlighted. (literal)
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it